Aclaris’ mixed PhIIb eczema data; Amgen licenses Xeris’ tech; Bolden Tx secures fundingnews2024-01-10T16:11:01+00:00January 10th, 2024|Endpoints News|
Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyoutnews2024-01-10T16:01:11+00:00January 10th, 2024|Endpoints News|
C4 Therapeutics cuts staff, restructures to focus on lead protein degradation programs, discovery pactsnews2024-01-10T13:15:23+00:00January 10th, 2024|Endpoints News|
LinkedUp, TianTi end legal dispute with Adimab over yeast-based antibody platformnews2024-01-10T12:29:13+00:00January 10th, 2024|Endpoints News|
CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinicnews2024-01-10T11:45:35+00:00January 10th, 2024|Endpoints News|
Alcon reports PhIII win for dry eye drug, plans mid-2024 FDA filingnews2024-01-10T11:22:27+00:00January 10th, 2024|Endpoints News|
#JPM24: Walgreens’ new CEO unpacks how the chain will survive as a standalone businessnews2024-01-10T06:48:14+00:00January 10th, 2024|Endpoints News|
#JPM24: Walgreens CEO says it would be easy for UK pharmacy operation Boots to run separately amid talks of splittingnews2024-01-10T06:31:03+00:00January 10th, 2024|Endpoints News|
#JPM24: Paul Hudson is ‘open-minded’ to M&A as he plots Sanofi’s transformationnews2024-01-09T23:13:39+00:00January 9th, 2024|Endpoints News|
#JPM24 quick hits: Vibe check; Maze’s next turn; AI at pharma companies + morenews2024-01-09T22:51:11+00:00January 9th, 2024|Endpoints News|
